Premium
O3–06–05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074
Author(s) -
Ross Joel,
Sharma Sanjiv K.,
Chatterjee Abhijit,
Winston Jaron,
Bottini Gabriella,
Franceschi Massimo,
Fernandez Mercedes,
Giardino Luciana,
Calzà Laura,
Norris Dottie,
Cicirello Helen,
Imbimbo Bruno
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.04.271
Subject(s) - medicine , adverse effect , tolerability , placebo , anesthesia , alternative medicine , pathology
or prior use of hormone therapy: mean treatment effects of -0.17 (-0.33, -0.01) and -0.25 (-0.42, -0.08) standard deviation units, respectively. Limitation:We are not able to address whether initiating hormone therapy earlier in the perimenopausal period affects cognitive function, either in the short or longer term. Conclusions: CEE-based therapies produced no overall sustained benefits or deficits to cognitive function when administered to early postmenopausal women aged 50-54 years.